PREDILIFE: TRIPLE OF REVENUES IN THE 1ST HALF OF 2022 – 08/30/2022 at 17:45


PREDILIFE reaps the first fruits of its B2B and B2B2C multi-channel distribution strategy

Villejuif, France, August 30, 2022, 5:45 p.m. – PREDILIFE

(Euronext Growth: ALPRE FR0010169920), a specialist in innovative pathology risk prediction solutions for personalized medicine, today announced its revenue for the first half of 2022.

In K€ Unaudited data

06/30/22

06/30/21

Variation

Turnover

151

39

x3.8

Acceleration of sales of prevention reports on 1

er

semester 2022

During the first half of 2022, PREDILIFE achieved a turnover of 151 K€, up 287% compared to the same period of the previous financial year.

The commercial strategy initiated by PREDILIFE since the 2

n/a

half of 2021 aimed at offering companies health checks for their employees is starting to bear its first fruits. Responding to a strong concern of both employers and employees, PREDILIFE health check-ups are very well received by companies in sectors as varied as insurance (Allianz), agri-food (Lactalis) or trade (Marionnaud). This growth in sales confirms the growing interest in predictive medicine and bears witness to the strong desire of companies to play a role in the health of their employees.

In a logic of distribution to the greatest number of multi-pathology assessments, PREDILIFE has also succeeded in surrounding itself with a large network of strategic partners of health insurance brokers like Mercer, 1

er

broker in the world, addressing 70% of CAC 40 companies in France, as well as mutual insurance companies now taking charge of the reimbursement of balance sheets such as Nuoma, the High Tech mutual insurance company.

Relying on renowned prescribing partners, PREDILIFE also continued to distribute MammoRisk® assessments to doctors for their patients. A breast cancer prediction model selected by the EU, MammoRisk® is also offered in the largest French hospitals and clinics (American Hospital, Henri Hartmann Breast Institute, French Breast Institute, etc.).

In addition, sales of 1

er

half of 2022 also saw growth in Europe, particularly in Italy, Belgium and Greece.

Stéphane Ragusa says: “

We are pleased with this good orientation of sales with such different players. These first customers each represent important segments that illustrate the broad growth potential of our markets in France and internationally.

“.

Favorable outlook

On the strength of these promising developments and the many partnerships under negotiation for several months, PREDILIFE shows its full confidence to continue its growth trajectory in 2022 and beyond.

About Predilife

PREDILIFE is a pioneer in the design and development of predictive tests that can allow each person to define their risk profile for the occurrence of serious diseases. It uses artificial intelligence methods applied to clinical medical data, genetics, imaging… PREDILIFE markets in Europe Mammorisk®, a breast cancer risk prediction test. The Company has also begun to extend this offer to other serious pathologies.

contacts

PREDILIFE Investor Relations

Stephane Ragusa

Chairman and CEO

[email protected]


CAPVALUE Press Relations

01 80 81 50 00

[email protected]


This post has the “? Actusnews SECURITY MASTER” service.


– SECURITY MASTER Key:

yJxpZcebl2aYxmueZJ2XaGiUa2aSxmHJa5WWl2dtZcrGa3FjxmpjbsaVZnBnlWdm

– To check this key:

https://www.security-master-key.com.



Regulated information:


Inside information:

– Press release on accounts, results


Full and original press release in PDF format:

https://www.actusnews.com/news/76020-bat_cp-predilife-cp-s1-2022-v4-sr_vf-1-2.pdf

© Copyright Actusnews Wire

Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com



Source link -86